B
Bull
Bull · 25%BLFS
$26.69
Scenario price
$38.610
+1.355 (+3.51%)At close
Loading chart…
- High
- 38.830
- Open
- 37.160
- VWAP
- 38.13
- Volume
- 4.45M
- Mkt Cap
- 944.41M
- Low
- 36.950
- Amount
- 169.53M
- EV/EBITDA, TTM
- 164.02
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
AI analysis of BioLife Solutions, Inc. (BLFS)
HoldBioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
Analyst Ratings (3)
-13.88% Downside
Buy
2 Buy
1 Hold
0 Sell
Current: 38.61
Low
32.00
Average
33.25
High
34.00
Benchmark
Hold
—
2026-08-10
Benchmark
2026-08-10
Price Target
—
Hold
Jefferies
Hold
$31
2026-07-23
Jefferies
2026-07-23
Price Target
$31
Hold
H.C. Wainwright
Neutral
$31
2026-07-23
H.C. Wainwright
2026-07-23
Price Target
$31
Neutral
TD Cowen
Hold
$31
2026-07-22
TD Cowen
2026-07-22
Price Target
$31
Hold
Craig-Hallum
Hold
$31
2026-07-22
Craig-Hallum
2026-07-22
Price Target
$31
Hold
Valuation Metrics
The current forward P/E ratio for BioLife Solutions, Inc. (BLFS) is 238.10, compared to its 5-year average forward P/E of -160.64.
Alphio AI Price Scenarios for BLFS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding BLFS
Events Timeline
News
8.510-06FoolFreshworks Joins S&P SmallCap 600 Index
2.009-23NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.509-11PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
8.508-18NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
7.007-28PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
BLFS FAQ — answered by Alphio AI
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.